FoundationOne™ Heme Enables Identification of Genomic Alterations Not Identified By Conventional Methods Across Hematologic Malignancies
Comprehensive Genomic Profiling Utilizing DNA and RNA Sequencing May Expand Treatment Options For Patients; Data Presented at
"These data demonstrate the feasibility of comprehensive genomic profiling in patients with hematologic malignancies, and represent a significant step forward in making this approach available in routine clinical care," said Dr. Levine. "FoundationOne Heme enables the identification of genomic alterations that are molecular drivers of each patient's cancer which may help to expand and inform treatment options for individual patients, advance the development of new therapies against these targets, and ultimately improve patient outcomes."
In this study, Memorial-Sloan Kettering and
Notably, the high accuracy of FoundationOne Heme enabled detection of clinically actionable1 genomic alterations that were not detected using standard clinical assays, including:
- IDH1/2 alterations in a spectrum of myeloid/lymphoid malignancies;
- Recurrent BRAF alterations in refractory CLL (chronic lymphocytic leukemia) and myeloma;
- Alterations in the JAK-STAT signaling pathway in diffuse-large B cell lymphoma.
"Cancer care is being transformed by the ability to perform comprehensive genomic analysis of an individual's tumor, and then using this molecular information to identify the most relevant targeted therapies or clinical trials for each patient based on their genomic profile," said
About FoundationOne™ Heme
FoundationOne Heme is a fully informative genomic profile for hematologic cancers (leukemia, lymphoma and myeloma), as well as many sarcomas and pediatric cancers, designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. It is Foundation Medicine's second commercially available targeted sequencing assay and was developed in collaboration with
About
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark, of
Cautionary Notes Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits to patients with hematologic cancers of next-generation sequencing, the ability of FoundationOneTM Heme to identify actionable alterations relevant to hematologic cancers, the feasibility and utility of FoundationOne Heme for use in routine clinical practice, and the release of data from a clinical study demonstrating the value FoundationOne Heme in the treatment of hematologic cancers. All such forward-looking statements are based on current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that FoundationOne Heme may not meet the clinical standards expected for the test; FoundationOne Heme may not be suitable for use in routine clinical practice; FoundationOne Heme may not have value in the treatment hematologic cancers; and FoundationOne Heme may not be readily available for clinical use as a result of FoundationOne Heme not achieving significant commercial adoption or reimbursement support or
1. Alterations are defined as clinically actionable if linked to an
Media Contact:
dan@purecommunicationsinc.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media